Trial Profile
Enhanced innate immunity and killing of respiratory pathogens by nicotinamide in patients with bronchiectasis
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Nicotinamide (Primary)
- Indications Bacterial infections; Bronchiectasis
- Focus Biomarker; Pharmacokinetics
- 31 Jul 2013 New trial record